REG - Scancell Hlds - PDMR Notification

Scancell HoldingsAnnouncement

06/12/2023 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231206:nRSF9067Va&default-theme=true

RNS Number : 9067V  Scancell Holdings Plc  06 December 2023

 

6 December 2023

 

Scancell Holdings plc

("Scancell" or the "Company")

 

PDMR Notification

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, announces that further to the
Company's announcement on the 1 December 2023 regarding the successful placing
of ordinary shares of nominal value of 0.1 pence in the Company ("Shares") and
the subscription for Shares by Dr Jean-Michel Cosséry and Professor Lindy
Durrant, the following Shares were issued on 5 December 2023:

 

                   Dr Jean-Michel
Cosséry                   454,545

                   Professor Lindy
Durrant                   272,727

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

  1   Details of the person discharging managerial responsibilities/person closely
      associated
 a)   Name                                                         Jean-Michel Cosséry
 2    Reason for the notification
 a)   Position/status                                              Chairman of Board and PDMR
 b)   Initial notification/Amendment                               Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         Scancell Holdings plc
 b)   LEI                                                          2138008RXEG856SNP666
 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares
 b)   Identification Code                                          GB00B63D3314
 c)   Nature of the transaction                                    Acquisition of ordinary shares

 d)   Price(s) and volume(s)                                       454,545 ordinary shares at £0.11 per share
 e)   Aggregated information

      - Aggregated volume                                          N/A (single transaction)

      - Price
 f)   Date of the transaction                                      5 December 2023
 g)   Place of the transaction                                     Outside a trading venue

 

  1   Details of the person discharging managerial responsibilities/person closely
      associated
 a)   Name                                                         Lindy Durant
 2    Reason for the notification
 a)   Position/status                                              Executive Director and PDMR
 b)   Initial notification/Amendment                               Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         Scancell Holdings plc
 b)   LEI                                                          2138008RXEG856SNP666
 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Acquisition of ordinary shares
 b)   Identification Code                                          GB00B63D3314
 c)   Nature of the transaction                                    Acquisition of ordinary shares

 d)   Price(s) and volume(s)                                       272,727 ordinary shares at £0.11 per share

 e)   Aggregated information

      - Aggregated volume                                          N/A (single transaction)

      - Price
 f)   Date of the transaction                                      5 December 2023
 g)   Place of the transaction                                     Outside a trading venue

 

 

 

 

-ENDS-

 

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 

 ICR Consilium                               +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh  scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHTFBTTMTJMBPJ